Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956857 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1GAAKDM4DHSD17B2 | |
| SCHEMBL5956964 | 0.92 | GAA (0.36) | GAAHSD17B2NFKB1NFKB2RELA | |
| SCHEMBL5956586 | 0.92 | GAA (0.36) | GAAHSD17B2NFKB1NFKB2RELA | |
| SCHEMBL5956538 | 0.92 | KDM4E (0.38) | KDM4EALDH1A1GAAKDM4DHSD17B2 | |
| SCHEMBL5956752 | 0.92 | KDM4E (0.38) | KDM4EALDH1A1GAAKDM4DHSD17B2 | |
| SCHEMBL5956827 | 0.91 | KDM4E (0.37) | KDM4EALDH1A1GAAKDM4DHSD17B2 | |
| SCHEMBL5956639 | 0.91 | KDM4E (0.37) | KDM4EALDH1A1GAAKDM4DHSD17B2 | |
| SCHEMBL5956787 | 0.82 | MEN1 (0.36) | GAAHSD17B2NFKB1NFKB2RELA | |
| SCHEMBL5956611 | 0.82 | MEN1 (0.36) | GAAHSD17B2NFKB1NFKB2RELA | |
| SCHEMBL5956661 | 0.81 | GAA (0.36) | GAAHSD17B2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | KDM4E 1686/4885ALDH1A1 2624/4885GAA 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.